

Legislative Appropriations Request

For Fiscal Years 2022 and 2023

**Submitted to the
Governor's Office of Budget and Policy
and the Legislative Budget Board by the**



**CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS**

**September 25, 2020
(Revised September 28, 2020)**

TABLE OF CONTENTS

Part I - Statement and Chart

A. Administrator's Statement	1.A.
B. Organizational Chart	1.B.
C. Certificate of Dual Submissions	1.C.

Part 2 - Summary of Request

Budget Overview-Biennial Amounts

A. Base Request by

Strategy.....	2.A.
B. Base Request by Method of Finance.....	2.B.
C. Base Request by Object of Expense.....	2.C.
D. Base Request by Objective Outcomes	2.D.
F. Total Request by Strategy.....	2.F.
G. Total Request Objective Outcomes.....	2.G.

Part 3 - Strategy and Rider Request

A. Strategy Request	3.A.
A.1 Program-Level Request.....	3A.1
B. Rider Revisions and Additions Request.....	3.B.

Part 4 - Strategy and Rider Request

A. Exceptional Item Request Schedule.....	4.A.
B. Exceptional Items Strategy Allocation Schedule	4.B.
C. Exceptional Items Strategy Request.....	4.C.

Part 6 – Support Schedules

A. Historically Underutilized Business Supporting Schedule	6.A.
E. Estimated Revenue Collections Supporting Schedule	6.E.
F. Advisory Committee Supporting Schedule	6.F.
L. Document Production Standards	6.L.

This page is intentionally left blank.

542 Cancer Prevention and Research Institute of Texas

CPRIT's mission is to expedite discoveries and innovations across Texas to reduce the burdens of cancer. CPRIT's Oversight Committee awarded its first cancer research grant in late 2009. Eleven years later, CPRIT has invested over \$2.6 billion - 95 percent of the original funding approved by Texans for grant awards - in 1,576 grants.

CPRIT's investments are critically important because, despite advances, cancer remains the leading cause of death for Texans under the age of 85, with 125 people dying from cancer every day. Although the tragic emotional and physical toll of cancer is incalculable, in purely economic terms cancer cost the state \$42.5 billion in direct medical expenses and mortality losses in 2019. This is \$2.2 billion more than 2018. Considering Texas' emerging demographics and growing population, the state's cost of cancer is unlikely to decline unless Texas makes significant and sustainable changes now.

The Perryman Group estimates that the total cost to the Texas economy, including the multiplier effects on business activity, are almost \$224.1 billion in reduced annual spending, \$110.5 billion in output losses per year, and 1,094,965 lost jobs from cancer treatment, morbidity, and mortality and the associated spillover effects. This represents about 5.8 percent of the total output of the Texas economy and 6.1 percent of employment. Cancer's cost to the Texas economy is trending upward; current projected costs and unemployment reflect an increase over 2018 figures.

Recognizing these economic metrics and cancer's emotional toll, the 2019 Texas Legislature committed to protecting and leveraging the state's unprecedented investment in innovative cancer research and prevention efforts. In a unanimous Senate vote and near-unanimous House vote, legislators authorized a statewide election to dedicate an additional \$3 billion to drive Texas' momentum in the fight against cancer into the next decade. On November 5, 2019, Texans responded, overwhelmingly approving Proposition 6.

CPRIT is now a \$6 billion, 20-year initiative — the largest state research investment in the history of the United States and the second largest cancer research and prevention program in the world. We are focused on the gains Texas can make over the next decade. CPRIT will work with state leadership and stakeholders to identify new opportunities for innovation in cancer research and prevention efforts in Texas.

The exceptional projects CPRIT funds are responsible for Texas' leadership in state-of-the-art cancer research and prevention efforts over the past decade. CPRIT uses a highly distinguished group of 200+ non-Texas scientists, health professionals, product development entrepreneurs and patient advocates who objectively review academic and translational research, company development and relocation, and cancer prevention proposals. Altogether, these experts have reviewed more than 8,900 applications since fall 2009.

Of the \$2.6 billion CPRIT has awarded as of August 31, 2020, 10% of our funding (244 grants) supports cancer prevention efforts throughout the state. CPRIT's academic and product development research award portfolio (1,332 grants) includes projects spanning the research and development continuum – basic (13.9% of funding), translational (24.8% of funding) and clinical (30.9% funding) research – as well as investments in recruiting (27.9% of funding) and training (2.5% of funding) the best cancer research talent in Texas.

CPRIT's enabling statute specifies three requirements that the agency adopted as its operational goals in its Agency Strategic Plan, Fiscal Years 2021-2025. The three goals and examples of key measures through May 2020 indicating achievement follow.

Attract, create, and expand research capabilities in higher education

-Recruit stellar researchers and their labs to Texas institutions from across the world: 213 researchers recruited

-Increase the likelihood that the National Cancer Institute will identify additional Texas institutions as designated and/or comprehensive cancer centers: 2 additional NCI

Administrator's Statement

9/22/2020 6:21:30PM

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas

comprehensive designated cancer centers and 1 designated cancer center named

- Stimulate receipt of new non-state research funds to Texas institutions: \$1.6 billion in direct follow-on funding to CPRIT academic grantees
- Establish core facilities to provide access to cutting-edge shared technology through capital instrumentation and technical expertise: 55 core facilities to 21 institutions established through CPRIT awards

Attract, create, and expand the capabilities of private entities and create high-quality new jobs

- Attract existing biotech companies from elsewhere to Texas and establish new companies in Texas: 42 biotech companies started, expanded, or brought to Texas through CPRIT awards
- Enhance existing venture capital biotech investment in Texas: CPRIT product development awards have increased biotech investment in Texas by \$479.9 million
- Stimulate private sector, follow-on investment in companies brought to Texas by CPRIT or created through CPRIT funding in Texas: CPRIT company awards have resulted in \$3.37 billion direct follow-on funding, a greater than 7-1 ratio between private sector and CPRIT funding
- Stimulate growth of the Texas economy: the 2019 gross economic impact of CPRIT operations, including secondary effects, was \$28.0 billion in annual spending and \$13.7 billion in output
- Increase the number of high quality new permanent jobs created in Texas: Over 10,100 direct permanent Texas jobs created in 2019 as well as 126,000 indirect jobs

Expedite innovation in research and enhance the potential of breakthroughs in prevention and cures

- Support new clinical trials or studies and increase the number of patients in CPRIT-funded clinical trials: 160 new clinical trials funded treating 26,213 patients
- Identify cancer precursors and cancers detected through CPRIT-funded screening awards: 22,119 cancer precursors and 4,059 cancers detected
- Establish nationally recognized teams and centers in Texas: among others, nationally recognized teams and centers in immunotherapy and childhood cancers
- Increase the number of academic peer-reviewed publications and patent applications resulting from academic and product development research: over 5,700 published findings and 475 patent applications

CPRIT's \$1.88 billion investment in cancer research at Texas institutions of higher education over the last 11 years is demonstrably making the state a national leader in cancer research and making Texas more competitive for National Cancer Institute (NCI) and National Institutes of Health (NIH) research dollars. CPRIT awards led to more than \$1 billion in new NCI and NIH research awards to Texas researchers. Particularly notable is the 18 percent increase in NCI funding in 2019 to The University of Texas MD Anderson Cancer Center, which garnered \$124 million - second only to the \$125 million received by Dana Farber Cancer Center in Massachusetts. Equally impressive is the 300+% growth in annual NCI funding to The University of Texas Southwestern Medical Center, which received \$55 million in 2019 compared to \$16 million a decade ago.

This increase in federal funding is encouraging and directly related to an increase in the number of nationally competitive cancer researchers in Texas since 2009. Before CPRIT, Texas had one NCI Designated Comprehensive Cancer Center — The University of Texas MD Anderson Cancer Center in Houston. Now there are three. In addition to MD Anderson, The University of Texas Southwestern Medical Center in Dallas and Baylor College of Medicine in Houston joined this prestigious group in 2015. CPRIT grants also helped The University of Texas Health Science Center at San Antonio, an NCI Designated Cancer Center, solidify its position and prepare to regain comprehensive status.

Why are these designations important? NCI centers anchor the national cancer research effort. There are currently 71 such centers in 36 states and the District of Columbia. These form the backbone of NCI's programs for studying and controlling cancer. NCI recognizes a Designated Cancer Center for its scientific leadership, resources, and depth and breadth of its research in basic, clinical and/or population science. Comprehensive Cancer Centers demonstrate an additional depth and breadth

542 Cancer Prevention and Research Institute of Texas

of research, as well as substantial transdisciplinary research that bridges these scientific areas.

As a result, Texans benefit through greater access to clinical trials to get advanced levels of cancer care not available through other health care providers. The increase in NCI cancer centers significantly enhances the state's medical education and research efforts, resulting in higher quality and greater levels of knowledge and specialization in Texas doctors treating patients. All of this elevates the state's reputation in medical care and advanced research.

CPRIT's product development research program also raises Texas' standing for innovative cancer treatment development at early stage companies. Small companies are an essential part of the drug development pipeline. According to pharmaceutical research company Iqvia, early stage biotech companies developed about 65% of the new drug therapies approved in the U.S. in 2018. CPRIT has awarded \$479.9 million in company awards since 2010. These 42 companies now directly employ some 700 people in Texas.

CPRIT is investing in companies that attract venture capital to Texas. Collectively, they have raised an additional \$3.37 billion in mostly private sector investments after receiving CPRIT awards. Without CPRIT, it is likely that the venture capital invested in Texas companies would have gone to the East or West Coasts, the historical loci of the life science industry. According to The Perryman Group, from 2016 to 2019, Texas had the seventh highest amount of venture capital investment in biosciences in the US at \$2.337 billion. During the same period, Texas was also in the top ten among states with 5,000 bioscience-related patents. Venture capital spending continues to grow in the US, totaling \$30 billion in 2018 – 2019, increasing from \$22 billion in 2017. CPRIT's product development research program significantly enhances the state's capacity to attract venture capital investments and grow the biosciences industry in Texas.

The companies supported by CPRIT are in industries that create substantial ripple effects for the state's economy. The Perryman Group estimates that total economic benefits of these CPRIT-funded firms include \$626.4 million in annual gross product and some 5,028 jobs (including multiplier effects). Even beyond the sizable increases in business activity, the presence of leading-edge, CPRIT-funded firms enhances Texas' position in key industries within the life sciences that have the potential to generate substantial growth and venture capital investment over time.

While it is critical that CPRIT continue to research and develop groundbreaking cancer drugs, devices and diagnostics, CPRIT's prevention projects taking place in communities throughout Texas are making a difference right now. CPRIT funds effective, evidenced-based cancer prevention programs focused primarily on increasing the availability of screenings for colorectal, breast, cervical, lung cancers, and hepatitis B and C among medically underserved Texans. In addition, CPRIT is funding HPV and hepatitis B vaccinations to prevent cancer and improving cancer education and awareness for the public and health care providers. Through August 2020, CPRIT has invested \$277.7 million in projects that have provided 6.6 million prevention services in all 254 Texas counties. Clinicians have identified more than 26,000 cancers or cancer precursors, increasing the likelihood that these Texans will join the growing number of cancer survivors.

SUMMARY OF APPROPRIATIONS REQUEST

CPRIT requests \$600 million in general obligation bond proceeds for the 2022-23 biennium as authorized in the Texas Constitution, Article III, Section 67. Since CPRIT is a special fund agency, the maximum dollar amount of its request is limited to the requested bond proceeds plus a small amount from license plate revenue and appropriated receipts authorized in general law which are restricted by the amount received for these purposes.

However, within its funding authority CPRIT requests two exceptional items. The first is an adjustment to address an appropriation shortfall for grant review and award operating costs that have permanently increased the agency's base administrative budget. These costs include increases in review council honoraria due to a rise in

Administrator's Statement

9/22/2020 6:21:30PM

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas

workload and membership for the review council chairs that were incorporated in modifications to the agency's Honoraria Policy adopted for FY 2020, product development grant application due diligence resulting from more applications undergoing diligence evaluations, and the outsourced pre- and post-award grant management support contract for the implementation and maintenance of information security enhancements to the electronic grant management platform. In addition, CPRIT initiated an interagency contract with the Texas Safekeeping Trust Company in FY 2021 to provide their asset management expertise to the agency to ensure the state's interest in CPRIT company grant assets are actively managed for maximum benefit to the state.

The second request is for eight (8) full-time equivalent (FTE) positions for additional compliance/accounting and program workload requirements.

CPRIT and its grantees are improving Texas' national standing in both cancer research and the biomedical industry with an extraordinarily low overhead. CPRIT's grantees may not spend more than 5 percent of grant funds on indirect costs. Because of appropriations limits, CPRIT minimizes operational costs for agency and grant management operations to maximize the funds available for substantive research and prevention grants. CPRIT's overhead comprises less than seven percent of the total amount appropriated to the agency annually.

Although CPRIT's seven percent overhead is laudable, it is only slightly more than one percent when considered in the context of active grants under management. As of August 2020, CPRIT is administering 550+ active grants totaling \$1.4 billion. CPRIT is sensitive to the need for publicly funded agencies to keep overhead as low as possible. However, the extremely low ratio between annual operating costs and total funds under active management may indicate insufficient resources dedicated to compliance, fiscal and program monitoring.

We worked with our internal auditors and others to determine existing industry standards for similar entities to identify a benchmark staffing level for CPRIT. Surprisingly, few comparable grant making entities exist and none with a defined statutory compliance program like CPRIT's. The only comparable state agency is the California Institute of Regenerative Medicine, which does not have a compliance operation as extensive as CPRIT. On the federal level, the NIH and NCI use program officers to work with grantees on policy questions but, unlike CPRIT, do not verify contracted project milestones, research progress, or expenditure accountability prior to disbursing grant funds. Instead, NIH and NCI operate on trust. From the NIH website:

"NIH and its recipient institutions share responsibility for compliance and oversight to ensure good stewardship of Federal funds. The relationship between NIH and its recipients is predicated on trust. Recipients are expected to properly administer sponsored activities and comply with applicable regulations and policies."

Unlike federal programs that shift fiscal and program accountability to the grantees, state law requires CPRIT to maintain a comprehensive compliance program and rigorous accounting verification of allowable expenditures to protect the state's significant investment in cancer research and prevention.

CPRIT's analysis of compliance program monitoring hours dedicated to ten distinct, required processes indicates an appropriate staffing level of 9.15 FTEs. CPRIT currently has six line compliance staff. CPRIT requests three additional compliance personnel to fill this gap. The additional Grant Compliance Specialists will address the increasing workload of performing the necessary annual grant compliance reviews, monitoring visits, and trainings for CPRIT's portfolio of 550+ active grants.

In addition to workload demands on the compliance program, CPRIT needs two new grant accountants and a general agency accountant. The two grant accountants will specialize in reviewing the financial reports of product development research grantees. The general agency accountant will support grant payment processing of the 550+ financial status reports completed every fiscal quarter as well as provide support on general agency budget and accounting processes to back up the single agency accountant.

542 Cancer Prevention and Research Institute of Texas

CPRIT requests two program FTEs—one program manager each for academic research and product development research. The number of FTEs assigned to each program has not increased since 2013. The additional FTEs will address increased workload demands resulting from a rise in research grant results data from both the awards under active management as well as completed awards and the demand for program resource availability. Program managers support the program chiefs by managing the flow of regular and extensive research progress report and grant change request approvals made via CPRIT's grant management system, responding to informational requests from grantees and grant applicants, preparing requests for applications, coordinating peer review meetings with CPRIT's third-party grant management contractor, coordinating program-related advisory committee meetings and reports, and coordinating and providing support for quarterly Oversight Committee and subcommittee meetings. The program managers also perform analysis of grant data that changes every quarter as grantees submit research progress reports as well as the announcement of new grant awards, which changes the composition of CPRIT's grant portfolio.

The new product development manager position will also assist in outreach efforts to increase national and in-state awareness of the availability of CPRIT awards to companies willing to start or relocate in Texas. Besides adding to the important life sciences industry in Texas, relocating companies in Texas seeds the executive level management pool necessary to mature and expand the young life science sector of the Texas economy. Industry experts often cite the relative lack of executive level expertise as a major factor that keeps Texas from competing equally with the East and West Coast for private sector life science investment. CPRIT product development research awards are an element in meeting state leadership's goal of making Texas the "third coast" for life sciences. Life sciences form the most sought-after industry cluster to generate the economic growth and high-quality jobs Texas needs to meet the challenges of the 21st Century.

The addition of the 8 new FTEs will exhaust CPRIT's available space in the Travis Building in the Capitol Complex, which the Texas Facilities Commission designed for a maximum of 40 FTEs in 2014. CPRIT notes that the state expects to complete construction of the new Health and Human Services Commission Building in North Austin in May 2021. HHSC currently leases a large footprint adjacent to CPRIT on the sixth floor of the Travis Building. CPRIT requests that the State makes a portion of this vacated space available for CPRIT's growth and authorize renovation of the new space.

The request also includes a recommended change to CPRIT-specific rider provision 4, Transfer Authority. This revision gives CPRIT's chief executive officer the same transfer authority authorized for all other agency executive directors to move a maximum of 20 percent from one item of appropriation to another within the requirements of Article IX, Section 14.01, rather than request approval from the Legislative Budget Board (LBB) for these transfers. To maintain legislative oversight for the appropriateness of any transfers, CPRIT would report any transfers made pursuant to this requested authority to the LBB.

The length of time necessary for CPRIT to receive LBB approval has seriously hindered our ability to address emerging issues related to IT security in a timely manner. CPRIT relies extensively on its electronic grant management platform to manage processes including receipt and review of several hundred grant applications each year, as well as the execution of grant contracts and facilitation of all aspects of grantee financial and compliance reporting and review. These processes are complex and performed across several different modules of the grant management platform that handles confidential, proprietary information related to pre-patent scientific discoveries. CPRIT receives and reviews system test reports on this IT platform regularly along with test reports of all other IT platforms utilized by CPRIT and managed by other third-party vendors or by CPRIT's IT staff. CPRIT's IT infrastructure undergoes regular review through internal audits. These audits have resulted in extensive operational modifications to implement IT security standards.

Addressing IT security concerns has required previously unforeseen procurement of contracted IT services or platforms. It is impossible to project in our biennial budget request what CPRIT may need 15 months into the future, let alone two or three years later. The time required to have transfers approved by our board, along with the delays caused by additional LBB approval, jeopardizes CPRIT's data security. A recent example occurred with CPRIT's implementation of statutorily mandated

Administrator's Statement

9/22/2020 6:21:30PM

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas

information technology security infrastructure in 2019. The Oversight Committee approved a budget request addressing this issue at its August 24, 2018, public meeting. CPRIT submitted the transfer request to the LBB three days later. CPRIT received LBB approval on November 16, 2018, 81 days after it made the request. This months-long delay made it impossible for CPRIT to take prompt action to address serious security safeguards. Prior to the 2018 request, CPRIT submitted two requests during the 2014-15 biennium that took 58 and 72 days for LBB approval. More recently, it took 67 days before the LBB approved a similar request made for FY 2021.

CHANGES IN STATE LAW AFFECTING AGENCY OPERATIONS

None affecting this request.

FUNDING REQUEST FOR PROGRAMS EXCEPTED FROM BASELINE REQUEST LIMITATION

None affecting this request.

SIGNIFICANT CHANGES IN POLICY

None affecting this request.

SIGNIFICANT EXTERNALITIES

Accommodating COVID-19 has had negligible effect on CPRIT's ability to address its constitutional and statutory mandates. However, doing so has required modifying operational processes to ensure the health and safety of the Oversight Committee, staff, and peer reviewers.

Examples of these adjustments include:

- Establishing an indefinite 100 percent remote work policy for agency staff;
- Convening Oversight Committee meetings by videoconference as authorized by gubernatorial executive order;
- Restricting all agency travel indefinitely unless specifically authorized by the chief executive officer and the chief operating officer;
- Cancelling all in-person peer review meetings in favor of videoconferences;
- Establishing an internal COVID-19 Work Group to meet by videoconference on a regular basis to resolve questions and provide guidance for grantees and applicants on issues related to the pandemic;
- Tracking CPRIT expenses and revenues related to COVID-19 for the LBB and the Governor's Office

The most painful adjustment made due to the pandemic was cancelling our major biennial conference scheduled for July 2020. We expected this conference to draw up to 1,000 researchers, clinicians, and community organizers to network about CPRIT-funded cancer activities and scientific advances. In addition, we placed the planning for "CPRIT 2.0" on hold during the first five months of the shutdown, but we are restarting efforts using video-conferenced meetings and other socially distanced means.

PURPOSE OF ANY NEW FUNDING BEING REQUESTED

Administrator's Statement

9/22/2020 6:21:30PM

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas

Not applicable.

CHANGES IN EXEMPT POSITIONS

CPRIT requests a 10% increase in the current exempt salary for the Chief Scientific Officer (CSO) from \$553,500 to \$608,850. Because the CSO position is an M.D. and/or Ph.D.-level practicing physician or scientist that is comparable in stature to medical school deans or senior medical research administrators, the legislature established the current amount using comparable salaries at health-related institutions of higher education. The legislature has not adjusted the CSO salary since 2013, when it approved the salary in place of an annual supplement from the now defunct CPRIT Foundation. In that same period, the average of comparable state salaries at Texas institutions of higher education has risen to \$819,960.

CPRIT is a unique hybrid between an institution of higher education and general state agency. Individuals with extensive university and/or industry experience are best suited to fill several CPRIT positions due to their subject matter expertise. For example, CPRIT's current CSO is the former director of the Harold Simmons Comprehensive Cancer at The University of Texas Southwestern Medical Center at Dallas. He currently oversees the awarding on average around \$180 million in new cancer research grants annually.

The increase will also be critical in recruiting a successor CSO, should that position become vacant. CPRIT must pay salaries competitive with those at our leading health science centers, health-related non-governmental organizations, and the private venture capital sector. The Oversight Committee and the Chief Executive Officer are committed only to providing salary increases to the incumbent CSO for merit-based high performance; any future increases would be based on evaluation of the incumbent's work product in relation to stipulated high expectations.

BACKGROUND CHECKS

CPRIT does not have specific authority to conduct background checks. Since January 2013, the agency has verified potential employees' eligibility to work in the United States through the E-Verify system during the hiring process.

GOVERNANCE

The Oversight Committee is CPRIT's governing body composed of three members appointed by the Governor, three by the Lieutenant Governor and three by the Speaker of the House of Representatives. One member appointed by each office must be a physician or scientist with extensive experience in the fields of oncology or public health; other appointments may include cancer survivors or family members of cancer patients.

Oversight Committee Member / Date of Term / Hometown

Donald "Dee" Margo, Presiding Officer, 2015-2021, El Paso
Mahendra C. Patel, M.D., Deputy Presiding Officer, 2017-2021, San Antonio
David A. Cummings, M.D., Secretary, 2018-2023, San Angelo
Ambrosio Hernandez, III, M.D., 2020-2025, Pharr
Will Montgomery, 2013-2023, Dallas

Administrator's Statement

9/22/2020 6:21:30PM


87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas

Cynthia Barberio Payne, 2020-2025, Spring Branch
William H. Rice, M.D., 2020-2025, Austin
Craig S. Rosenfeld, M.D., 2013-expired, Dallas
one vacancy



CANCER PREVENTION & RESEARCH INSTITUTE OF TEXAS



This page is intentionally left blank.



CERTIFICATE

Agency Name Cancer Prevention and Research Institute of Texas

This is to certify that the information contained in the agency Legislative Appropriation Request filed with the Legislative Budget Board (LBB) and the Governor's Office Budget Division (Governor's Office) is accurate to the best of my knowledge and that the electronic submission to the LBB via the Automated Budget and Evaluation System of Texas (ABEST) and the PDF file submitted via the LBB Document Submission application are identical.

Additionally, should it become likely at any time that unexpended balances will accrue for any account, the LBB and the Governor's Office will be notified in writing in accordance with Article IX, Section 7.01 (2020-21 GAA).

Chief Executive Officer or Presiding Judge

Wayne R. Roberts
Signature

Wayne R. Roberts
Printed Name

Chief Executive Officer
Title

9/22/20
Date

Board or Commission Chair

Donald "Dee" Margo
Signature

Donald "Dee" Margo
Printed Name

Presiding Officer
Title

9/23/20
Date

Chief Financial Officer

Heidi McConnell
Signature

Heidi McConnell
Printed Name

Chief Operating Officer
Title

9/23/20
Date

This page is intentionally left blank.

Budget Overview - Biennial Amounts
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas
Appropriation Years: 2022-23

		GENERAL REVENUE FUNDS		GR DEDICATED		FEDERAL FUNDS		OTHER FUNDS		ALL FUNDS		EXCEPTIONAL ITEM FUNDS
		2020-21	2022-23	2020-21	2022-23	2020-21	2022-23	2020-21	2022-23	2020-21	2022-23	2022-23
Goal: 1. Create and Expedite Innovation in Cancer Research and Prevention Servs												
1.1.1. Award Cancer Research Grants								498,249,332	503,240,208	498,249,332	503,240,208	(5,943,147)
1.1.2. Award Cancer Prevention Grants								56,120,157	56,092,162	56,120,157	56,092,162	(660,351)
1.1.3. Grant Review And Award Operations								31,290,698	25,773,460	31,290,698	25,773,460	6,543,498
Total, Goal								585,660,187	585,105,830	585,660,187	585,105,830	(60,000)
Goal: 2. Indirect Administration												
2.1.1. Indirect Administration								8,928,931	8,760,106	8,928,931	8,760,106	60,000
Total, Goal								8,928,931	8,760,106	8,928,931	8,760,106	60,000
Total, Agency								594,589,118	593,865,936	594,589,118	593,865,936	
Total FTEs										36.0	36.0	8.0

542 Cancer Prevention and Research Institute of Texas

Goal / Objective / STRATEGY	Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
1 Create and Expedite Innovation in Cancer Research and Prevention Servs					
1 <i>Cancer Research and Prevention Projects</i>					
1 AWARD CANCER RESEARCH GRANTS	209,250,310	249,113,804	249,135,528	251,620,104	251,620,104
2 AWARD CANCER PREVENTION GRANTS	26,826,443	28,070,076	28,050,081	28,046,081	28,046,081
3 GRANT REVIEW AND AWARD OPERATIONS	13,634,462	13,346,574	17,944,124	12,886,730	12,886,730
TOTAL, GOAL 1	\$249,711,215	\$290,530,454	\$295,129,733	\$292,552,915	\$292,552,915
2 Indirect Administration					
1 <i>Indirect Administration</i>					
1 INDIRECT ADMINISTRATION	2,917,525	4,456,597	4,472,334	4,380,053	4,380,053
TOTAL, GOAL 2	\$2,917,525	\$4,456,597	\$4,472,334	\$4,380,053	\$4,380,053
TOTAL, AGENCY STRATEGY REQUEST	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968
TOTAL, AGENCY RIDER APPROPRIATIONS REQUEST*				\$0	\$0
GRAND TOTAL, AGENCY REQUEST	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968

2.A. Summary of Base Request by Strategy

9/22/2020 5:59:00PM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

542 Cancer Prevention and Research Institute of Texas

Goal / Objective / STRATEGY	Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
<u>METHOD OF FINANCING:</u>					
Other Funds:					
666 Appropriated Receipts	72,050	40,000	40,000	40,000	40,000
780 Bond Proceed-Gen Obligat	252,556,690	294,910,873	299,547,067	296,881,968	296,881,968
802 Lic Plate Trust Fund No. 0802, est	0	36,178	15,000	11,000	11,000
SUBTOTAL	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968
TOTAL, METHOD OF FINANCING	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968

*Rider appropriations for the historical years are included in the strategy amounts.

2.B. Summary of Base Request by Method of Finance

9/23/2020 8:37:37AM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas			
METHOD OF FINANCING		Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
<u>OTHER FUNDS</u>						
<u>666</u>	Appropriated Receipts					
	REGULAR APPROPRIATIONS					
	Regular Appropriations from MOF Table (2018-2019 GAA)					
		\$40,000	\$0	\$0	\$0	\$0
	Comments: Product Development Research Grant Application Fees					
	Regular Appropriations from MOF Table (2020-2021 GAA)					
		\$0	\$40,000	\$40,000	\$0	\$0
	Comments: Product Development Research Grant Application Fees					
	Regular Appropriations from MOF Table (2022-2023 GAA)					
		\$0	\$0	\$0	\$40,000	\$40,000
	Comments: Product Development Research Grant Application Fees					
	RIDER APPROPRIATION					
	Art IX, Sec 8.02, Reimbursements and Payments (2018-2019 GAA)					
		\$7,600	\$0	\$0	\$0	\$0
	Comments: Product Development Research Grant Applications Fees; the amount includes a \$100 donation to CPRIT not recognized in the 2020 Operating Budget					
	UNEXPENDED BALANCES AUTHORITY					

2.B. Summary of Base Request by Method of Finance

9/23/2020 8:37:37AM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 542		Agency name: Cancer Prevention and Research Institute of Texas				
METHOD OF FINANCING		Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
<u>OTHER FUNDS</u>						
Art IX, Sec. 8.02 Reimbursement and Payments (2018-2019 GAA)						
		\$24,450	\$0	\$0	\$0	\$0
Comments: Product Development Research Grant Application Fees UB						
TOTAL,	Appropriated Receipts	\$72,050	\$40,000	\$40,000	\$40,000	\$40,000
<u>780</u>	Bond Proceeds - General Obligation Bonds					
REGULAR APPROPRIATIONS						
Regular Appropriation from MOF Table (2018-2019 GAA)						
		\$300,000,000	\$0	\$0	\$0	\$0
Regular Appropriations from MOF Table (2020-2021 GAA)						
		\$0	\$300,000,000	\$300,000,000	\$0	\$0
Regular Appropriations from MOF Table (2022-2023 GAA)						
		\$0	\$0	\$0	\$300,000,000	\$300,000,000
TRANSFERS						
Art I, I-15, Rider 5 Transfer to Department of State Health Services for the Cancer Registry (2018-2019 GAA)						

2.B. Summary of Base Request by Method of Finance

9/23/2020 8:37:37AM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 542	Agency name: Cancer Prevention and Research Institute of Texas				
METHOD OF FINANCING	Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
<u>OTHER FUNDS</u>					
	\$(2,969,554)	\$0	\$0	\$0	\$0
Art I, I-15, Rider 5 Transfer to Department of State Health Services for the Cancer Registry (2020-2021 GAA)	\$0	\$(3,118,032)	\$(3,118,032)	\$0	\$0
Art I, I-15, Rider 5 Transfer to Department of State Health Services for the Cancer Registry (2022-2023 GAA)	\$0	\$0	\$0	\$(3,118,032)	\$(3,118,032)
<i>LAPSED APPROPRIATIONS</i>					
Regular Appropriations from MOF Table (2018-2019 GAA)	\$(44,526,789)	\$0	\$0	\$0	\$0
Comments: The FY 2019 lapse is a combination of \$43.7 million in uncommitted grant funds due to grant award declines and \$799,879 in unexpended operating funds due to contracted vendor payments being less than encumbered and salary savings from staff turnover and vacancies.					
<i>UNEXPENDED BALANCES AUTHORITY</i>					
Art I, I-17, Rider 9 Unexpended Balances between the biennium (2020-2021 GAA)	\$(694,004)	\$694,004	\$0	\$0	\$0
Art I, I-15, Rider 8 Unexpended Balances within the Biennium (2018-2019 GAA)					

2.B. Summary of Base Request by Method of Finance

9/23/2020 8:37:37AM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 542		Agency name: Cancer Prevention and Research Institute of Texas				
METHOD OF FINANCING		Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
<u>OTHER FUNDS</u>						
		\$747,037	\$0	\$0	\$0	\$0
Art I, I-15, Rider 8 Unexpended Balances within the Biennium (2020-2021 GAA)		\$0	\$(2,665,099)	\$2,665,099	\$0	\$0
TOTAL,	Bond Proceeds - General Obligation Bonds	\$252,556,690	\$294,910,873	\$299,547,067	\$296,881,968	\$296,881,968
<u>802</u>	License Plate Trust Fund Account No. 0802, estimated					
	<i>REGULAR APPROPRIATIONS</i>					
	Regular Appropriations from MOF Table (2018-2019 GAA)	\$15,000	\$0	\$0	\$0	\$0
	Comments: License Plate Revenue from Texans Conquer Cancer & Cancer of Unknown Origin Awareness plates					
	Regular Appropriations from MOF Table (2020-2021 GAA)	\$0	\$15,000	\$15,000	\$0	\$0
	Comments: License Plate Revenue from Texans Conquer Cancer & Cancer of Unknown Origin Awareness plates					
	Regular Appropriations from MOF Table (2022-2023 GAA)	\$0	\$0	\$0	\$11,000	\$11,000

2.B. Summary of Base Request by Method of Finance

9/23/2020 8:37:37AM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 542		Agency name: Cancer Prevention and Research Institute of Texas				
METHOD OF FINANCING		Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
<u>OTHER FUNDS</u>						
Comments: License Plate Revenue from Texans Conquer Cancer & Cancer of Unknown Origin Awareness plates						
<i>LAPSED APPROPRIATIONS</i>						
Unrealized license plate revenue						
		\$(4,704)	\$0	\$0	\$0	\$0
<i>UNEXPENDED BALANCES AUTHORITY</i>						
Art IX, IX-44, Sec. 8.13 Appropriation of Specialty License Plate Receipts (2020-2021 GAA)						
		\$(21,178)	\$21,178	\$0	\$0	\$0
Comments: License Plate Revenue from Texans Conquer Cancer & Cancer of Unknown Primary Origin Awareness Plates						
Art I, I-14, Rider 2 Appropriation of License Plate Receipts (2018-2019 GAA)						
		\$10,882	\$0	\$0	\$0	\$0
Comments: License Plate Revenue from Texans Conquer Cancer & Cancer of Unknown Primary Origin Awareness Plates						
TOTAL,	License Plate Trust Fund Account No. 0802, estimated					
		\$0	\$36,178	\$15,000	\$11,000	\$11,000
TOTAL, ALL	OTHER FUNDS					
		\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968

2.B. Summary of Base Request by Method of Finance

9/23/2020 8:37:37AM

87th Regular Session, Agency Submission, Version 1

Automated Budget and Evaluation System of Texas (ABEST)

Agency code: 542	Agency name: Cancer Prevention and Research Institute of Texas				
METHOD OF FINANCING	Exp 2019	Est 2020	Bud 2021	Req 2022	Req 2023
GRAND TOTAL	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968
FULL-TIME-EQUIVALENT POSITIONS					
REGULAR APPROPRIATIONS					
Regular Appropriations from MOF Table (2020-21 GAA)	0.0	36.0	36.0	0.0	0.0
Regular Appropriations from MOF Table (2018-19 GAA)	35.0	0.0	0.0	0.0	0.0
Regular Appropriations from MOF Table (2022-23 GAA)	0.0	0.0	0.0	36.0	36.0
UNAUTHORIZED NUMBER OVER (BELOW) CAP					
Unauthorized Number Over (Below) Cap	(0.5)	(1.6)	0.0	0.0	0.0
Comments: Vacant Position(s)Staff Turnover					
TOTAL, ADJUSTED FTES	34.5	34.4	36.0	36.0	36.0
NUMBER OF 100% FEDERALLY FUNDED FTEs					

2.C. Summary of Base Request by Object of Expense

9/22/2020 6:00:41PM

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)**542 Cancer Prevention and Research Institute of Texas**

OBJECT OF EXPENSE	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
1001 SALARIES AND WAGES	\$4,589,191	\$4,528,629	\$4,780,509	\$4,780,509	\$4,780,509
1002 OTHER PERSONNEL COSTS	\$135,082	\$96,811	\$83,785	\$83,785	\$83,785
2001 PROFESSIONAL FEES AND SERVICES	\$11,184,173	\$12,254,414	\$16,618,416	\$11,528,659	\$11,528,659
2003 CONSUMABLE SUPPLIES	\$10,020	\$24,000	\$24,000	\$24,000	\$24,000
2004 UTILITIES	\$36,871	\$72,032	\$70,600	\$70,600	\$70,600
2005 TRAVEL	\$50,217	\$110,000	\$90,000	\$90,000	\$90,000
2006 RENT - BUILDING	\$15,946	\$11,000	\$11,000	\$11,000	\$11,000
2007 RENT - MACHINE AND OTHER	\$17,321	\$32,172	\$32,172	\$32,172	\$32,172
2009 OTHER OPERATING EXPENSE	\$513,166	\$674,113	\$705,976	\$646,058	\$646,058
4000 GRANTS	\$236,076,753	\$277,183,880	\$277,185,609	\$279,666,185	\$279,666,185
OOE Total (Excluding Riders)	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968
OOE Total (Riders)					
Grand Total	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968

2.D. Summary of Base Request Objective Outcomes
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation system of Texas (ABEST)

9/28/2020 9:23:50AM

542 Cancer Prevention and Research Institute of Texas					
Goal/ Objective / Outcome	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
1 Create and Expedite Innovation in Cancer Research and Prevention Servs					
1 Cancer Research and Prevention Projects					
1 Non-State Funds Leveraged as Match for Research Grants (in millions)					
	94.90	17.90	22.90	20.20	20.60
2 Total Research Matching Fund Expenditures					
	106,085,231.00	45,160,515.00	76,200,000.00	40,500,000.00	41,300,000.00
3 % TX Regions w/ Cancer Prevention Services and Activities Initiated					
	100.00%	100.00%	100.00%	100.00%	100.00%
4 Percentage of Grantees Receiving Compliance Training					
	100.00%	100.00%	100.00%	100.00%	100.00%

This page is intentionally left blank.

2.E. Summary of Exceptional Items Request
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/22/2020
TIME : 6:15:33PM

Agency code: **542**

Agency name: **Cancer Prevention and Research Institute of Texas**

Priority	Item	2022			2023			Biennium	
		GR and GR/GR Dedicated	All Funds	FTEs	GR and GR Dedicated	All Funds	FTEs	GR and GR Dedicated	All Funds
1	Maintain Level Funding Grant		\$0			\$0			\$0
2	8 New Full Time Positions		\$0	8.0		\$0	8.0		\$0
Total, Exceptional Items Request			\$0	8.0		\$0	8.0		\$0

Method of Financing

General Revenue

General Revenue - Dedicated

Federal Funds

Other Funds

	0	0	0
\$0	\$0	\$0	\$0

Full Time Equivalent Positions

8.0

8.0

Number of 100% Federally Funded FTEs

2.F. Summary of Total Request by Strategy
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE : 9/28/2020
TIME : 4:15:46PM

Agency code: 542	Agency name: Cancer Prevention and Research Institute of Texas					
Goal/Objective/STRATEGY	Base 2022	Base 2023	Exceptional 2022	Exceptional 2023	Total Request 2022	Total Request 2023
1 Create and Expedite Innovation in Cancer Research and Prevention Se						
1 Cancer Research and Prevention Projects						
1 AWARD CANCER RESEARCH GRANTS	\$251,620,104	\$251,620,104	\$(2,979,443)	\$(2,963,704)	\$248,640,661	\$248,656,400
2 AWARD CANCER PREVENTION GRANTS	28,046,081	28,046,081	(331,050)	(329,301)	27,715,031	27,716,780
3 GRANT REVIEW AND AWARD OPERATIONS	12,886,730	12,886,730	3,212,165	3,212,165	16,098,895	16,098,895
TOTAL, GOAL 1	\$292,552,915	\$292,552,915	\$(98,328)	\$(80,840)	\$292,454,587	\$292,472,075
2 Indirect Administration						
1 Indirect Administration						
1 INDIRECT ADMINISTRATION	4,380,053	4,380,053	98,328	80,840	4,478,381	4,460,893
TOTAL, GOAL 2	\$4,380,053	\$4,380,053	\$98,328	\$80,840	\$4,478,381	\$4,460,893
TOTAL, AGENCY STRATEGY REQUEST	\$296,932,968	\$296,932,968	\$0	\$0	\$296,932,968	\$296,932,968
TOTAL, AGENCY RIDER APPROPRIATIONS REQUEST						
GRAND TOTAL, AGENCY REQUEST	\$296,932,968	\$296,932,968	\$0	\$0	\$296,932,968	\$296,932,968

2.F. Summary of Total Request by Strategy
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE : 9/28/2020
TIME : 4:15:46PM

Agency code: 542		Agency name: Cancer Prevention and Research Institute of Texas					
Goal/Objective/STRATEGY		Base 2022	Base 2023	Exceptional 2022	Exceptional 2023	Total Request 2022	Total Request 2023
Other Funds:							
666	Appropriated Receipts	\$40,000	\$40,000	\$0	\$0	\$40,000	\$40,000
780	Bond Proceed-Gen Obligat	296,881,968	296,881,968	0	0	296,881,968	296,881,968
802	Lic Plate Trust Fund No. 0802, est	11,000	11,000	0	0	11,000	11,000
		\$296,932,968	\$296,932,968	\$0	\$0	\$296,932,968	\$296,932,968
TOTAL, METHOD OF FINANCING		\$296,932,968	\$296,932,968	\$0	\$0	\$296,932,968	\$296,932,968
FULL TIME EQUIVALENT POSITIONS		36.0	36.0	8.0	8.0	44.0	44.0

This page is intentionally left blank.

2.G. Summary of Total Request Objective Outcomes
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation system of Texas (ABEST)

Date : 9/22/2020

Time: 6:17:06PM

Agency code: **542**

Agency name: **Cancer Prevention and Research Institute of Texas**

Goal/ Objective / Outcome

	BL 2022	BL 2023	Excp 2022	Excp 2023	Total Request 2022	Total Request 2023
1	Create and Expedite Innovation in Cancer Research and Prevention Servs					
1	<i>Cancer Research and Prevention Projects</i>					
	1 Non-State Funds Leveraged as Match for Research Grants (in millions)					
	20.20	20.60			20.20	20.60
	2 Total Research Matching Fund Expenditures					
	40,500,000.00	41,300,000.00			40,500,000.00	41,300,000.00
	3 % TX Regions w/ Cancer Prevention Services and Activities Initiated					
	100.00%	100.00%			100.00%	100.00%
	4 Percentage of Grantees Receiving Compliance Training					
	100.00%	100.00%			100.00%	100.00%

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs
OBJECTIVE: 1 Cancer Research and Prevention Projects
STRATEGY: 1 Award Cancer Research Grants

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
Output Measures:						
KEY 1	Number Entities Relocating to TX for Cancer-Research Related Projects	0.00	2.00	1.00	1.00	1.00
2	# of Researchers Recruited	24.00	19.00	20.00	20.00	20.00
Explanatory/Input Measures:						
1	Number of Research Grant Awards	110.00	117.00	79.00	79.00	79.00
2	Average Dollar Amount of Research Grants Awarded	1,556,083.00	2,200,000.00	2,200,000.00	2,200,000.00	2,200,000.00
KEY 3	Number of Published Articles	1,074.00	888.00	1,000.00	1,000.00	1,000.00
KEY 4	Number of New Jobs Created and Maintained	3,455.00	3,139.00	1,500.00	3,000.00	3,000.00
Objects of Expense:						
4000	GRANTS	\$209,250,310	\$249,113,804	\$249,135,528	\$251,620,104	\$251,620,104
TOTAL, OBJECT OF EXPENSE		\$209,250,310	\$249,113,804	\$249,135,528	\$251,620,104	\$251,620,104
Method of Financing:						
780	Bond Proceed-Gen Obligat	\$209,250,310	\$249,113,804	\$249,135,528	\$251,620,104	\$251,620,104
SUBTOTAL, MOF (OTHER FUNDS)		\$209,250,310	\$249,113,804	\$249,135,528	\$251,620,104	\$251,620,104

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs
OBJECTIVE: 1 Cancer Research and Prevention Projects
STRATEGY: 1 Award Cancer Research Grants

Service Categories:

Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$251,620,104	\$251,620,104
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$209,250,310	\$249,113,804	\$249,135,528	\$251,620,104	\$251,620,104

FULL TIME EQUIVALENT POSITIONS:

STRATEGY DESCRIPTION AND JUSTIFICATION:

The goal of CPRIT's Academic Research and Product Development Research Programs is to expedite innovation in the area of cancer research by enhancing the potential for a medical or scientific breakthrough in the prevention of cancer and cures for cancer and create or expand the research capabilities of public or private institutions of higher education and other public or private entities to get more cures to cancer patients.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

CPRIT's investments are important because, despite advances, cancer remains the leading cause of death for Texans under the age of 85, with 125 people dying from cancer every day in Texas. Although the emotional and physical toll of cancer is incalculable, in purely economic terms, cancer cost the state \$42.5 billion in direct medical costs and mortality losses in 2019. This is \$2.2 billion more than 2018. Considering Texas' emerging demographics and growing population, the state's cost of cancer is unlikely to decline unless Texas makes significant and sustainable changes now.

Academic research projects are awarded to public and private institutions of higher education. Texas is fortunate to have numerous prestigious universities from which originate applications for CPRIT to support. Funded projects range from basic research into the fundamentals of cancer science to early translational activities that begin moving basic research into the development stage for clinical (bedside) use. Product development research projects fund early translational research at existing or nascent Texas companies or companies that are willing to relocate to Texas to develop their cancer-related product.

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs
OBJECTIVE: 1 Cancer Research and Prevention Projects Service Categories:
STRATEGY: 1 Award Cancer Research Grants Service: 21 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2020 + Bud 2021)</u>	<u>Baseline Request (BL 2022 + BL 2023)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$498,249,332	\$503,240,208	\$4,990,876	\$4,990,876	The difference is CPRIT's requests to transfer funds from this strategy to the direct and indirect cost administration strategies to cover increased contractual and other operating costs.
			\$4,990,876	Total of Explanation of Biennial Change

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs
OBJECTIVE: 1 Cancer Research and Prevention Projects
STRATEGY: 2 Award Cancer Prevention Grants

Service Categories:

Service: 23 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
Output Measures:						
KEY 1	Number of Cancer Prevention and Control Services Provided	949,869.00	656,628.00	500,000.00	700,000.00	700,000.00
Explanatory/Input Measures:						
KEY 1	Annual Age-adjusted Cancer Mortality Rate	146.10	142.90	145.20	143.00	141.00
Objects of Expense:						
4000	GRANTS	\$26,826,443	\$28,070,076	\$28,050,081	\$28,046,081	\$28,046,081
TOTAL, OBJECT OF EXPENSE		\$26,826,443	\$28,070,076	\$28,050,081	\$28,046,081	\$28,046,081
Method of Financing:						
780	Bond Proceed-Gen Obligat	\$26,826,443	\$28,033,898	\$28,035,081	\$28,035,081	\$28,035,081
802	Lic Plate Trust Fund No. 0802, est	\$0	\$36,178	\$15,000	\$11,000	\$11,000
SUBTOTAL, MOF (OTHER FUNDS)		\$26,826,443	\$28,070,076	\$28,050,081	\$28,046,081	\$28,046,081
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$28,046,081	\$28,046,081
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$26,826,443	\$28,070,076	\$28,050,081	\$28,046,081	\$28,046,081
FULL TIME EQUIVALENT POSITIONS:						

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 2 Award Cancer Prevention Grants

Service: 23

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
------	-------------	----------	----------	----------	---------	---------

STRATEGY DESCRIPTION AND JUSTIFICATION:

The Prevention Program's goal is to establish effective evidence-based cancer control and prevention programs across Texas mobilizing public, private, and volunteer agencies and individuals to enhance the availability and quality of these services .

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

CPRIT's investments are important because, despite advances, cancer remains the leading cause of death for Texans under the age of 85, with 125 people dying from cancer every day in Texas. Although the emotional and physical toll of cancer is incalculable, in purely economic terms, cancer cost the state \$42.5 billion in direct medical costs and mortality losses in 2019. This is \$2.2 billion more than 2018. Considering Texas' emerging demographics and growing population, the state's cost of cancer is unlikely to decline unless Texas makes significant and sustainable changes now.

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 2 Award Cancer Prevention Grants

Service: 23

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2020 + Bud 2021)</u>	<u>Baseline Request (BL 2022 + BL 2023)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$56,120,157	\$56,092,162	\$(27,995)	\$(29,178)	The reduction in license plate trust fund unexpended balances carried forward and a decrease in the license plate revenue assumptions.
			\$1,183	Prevention grant funds that were not obligated in awards in FY 2020.
			<u>\$(27,995)</u>	Total of Explanation of Biennial Change

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs
OBJECTIVE: 1 Cancer Research and Prevention Projects
STRATEGY: 3 Grant Review and Award Operations

Service Categories:

Service: 09 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
Output Measures:						
1	Number of Grants Reviewed for Compliance	349.00	175.00	200.00	200.00	200.00
Objects of Expense:						
1001	SALARIES AND WAGES	\$3,250,017	\$3,065,058	\$2,993,084	\$2,993,084	\$2,993,084
1002	OTHER PERSONNEL COSTS	\$99,069	\$58,026	\$45,000	\$45,000	\$45,000
2001	PROFESSIONAL FEES AND SERVICES	\$10,208,149	\$10,029,975	\$14,717,473	\$9,719,997	\$9,719,997
2004	UTILITIES	\$16,864	\$13,432	\$12,000	\$12,000	\$12,000
2005	TRAVEL	\$24,460	\$65,000	\$45,000	\$45,000	\$45,000
2009	OTHER OPERATING EXPENSE	\$35,903	\$115,083	\$131,567	\$71,649	\$71,649
TOTAL, OBJECT OF EXPENSE		\$13,634,462	\$13,346,574	\$17,944,124	\$12,886,730	\$12,886,730
Method of Financing:						
666	Appropriated Receipts	\$72,050	\$40,000	\$40,000	\$40,000	\$40,000
780	Bond Proceed-Gen Obligat	\$13,562,412	\$13,306,574	\$17,904,124	\$12,846,730	\$12,846,730
SUBTOTAL, MOF (OTHER FUNDS)		\$13,634,462	\$13,346,574	\$17,944,124	\$12,886,730	\$12,886,730

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 3 Grant Review and Award Operations

Service: 09

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$12,886,730	\$12,886,730
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$13,634,462	\$13,346,574	\$17,944,124	\$12,886,730	\$12,886,730
FULL TIME EQUIVALENT POSITIONS:		24.2	24.0	24.5	24.5	24.5

STRATEGY DESCRIPTION AND JUSTIFICATION:

This strategy summarizes CPRIT's direct operational costs to receive, review, award, and monitor cancer research and prevention grants.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

These operating costs fund the online receipt of grant applications, independent expert peer review of applications, and the monitoring and review of required grant reports of the approximately 400 active awards.

542 Cancer Prevention and Research Institute of Texas

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 3 Grant Review and Award Operations

Service: 09

Income: A.2

Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2020 + Bud 2021)</u>	<u>Baseline Request (BL 2022 + BL 2023)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$31,290,698	\$25,773,460	\$(5,517,238)	\$(4,905,976)	The amount of transfers authorized from the cancer research strategy (1.1.1) to cover contractual and other operating expenses in 2020-21.
			\$(631,262)	Unexpended balances for several contractual services carried forward from FY 2019.
			\$20,000	In FY 2021 made budget adjustment moving \$20,000 into indirect administration
			\$(5,517,238)	Total of Explanation of Biennial Change

542 Cancer Prevention and Research Institute of Texas

GOAL: 2 Indirect Administration
OBJECTIVE: 1 Indirect Administration
STRATEGY: 1 Indirect Administration

Service Categories:

Service: 09 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
Objects of Expense:						
1001	SALARIES AND WAGES	\$1,339,174	\$1,463,571	\$1,787,425	\$1,787,425	\$1,787,425
1002	OTHER PERSONNEL COSTS	\$36,013	\$38,785	\$38,785	\$38,785	\$38,785
2001	PROFESSIONAL FEES AND SERVICES	\$976,024	\$2,224,439	\$1,900,943	\$1,808,662	\$1,808,662
2003	CONSUMABLE SUPPLIES	\$10,020	\$24,000	\$24,000	\$24,000	\$24,000
2004	UTILITIES	\$20,007	\$58,600	\$58,600	\$58,600	\$58,600
2005	TRAVEL	\$25,757	\$45,000	\$45,000	\$45,000	\$45,000
2006	RENT - BUILDING	\$15,946	\$11,000	\$11,000	\$11,000	\$11,000
2007	RENT - MACHINE AND OTHER	\$17,321	\$32,172	\$32,172	\$32,172	\$32,172
2009	OTHER OPERATING EXPENSE	\$477,263	\$559,030	\$574,409	\$574,409	\$574,409
TOTAL, OBJECT OF EXPENSE		\$2,917,525	\$4,456,597	\$4,472,334	\$4,380,053	\$4,380,053
Method of Financing:						
780	Bond Proceed-Gen Obligat	\$2,917,525	\$4,456,597	\$4,472,334	\$4,380,053	\$4,380,053
SUBTOTAL, MOF (OTHER FUNDS)		\$2,917,525	\$4,456,597	\$4,472,334	\$4,380,053	\$4,380,053

542 Cancer Prevention and Research Institute of Texas

GOAL: 2 Indirect Administration
OBJECTIVE: 1 Indirect Administration
STRATEGY: 1 Indirect Administration

Service Categories:

Service: 09 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
TOTAL, METHOD OF FINANCE (INCLUDING RIDERS)					\$4,380,053	\$4,380,053
TOTAL, METHOD OF FINANCE (EXCLUDING RIDERS)		\$2,917,525	\$4,456,597	\$4,472,334	\$4,380,053	\$4,380,053
FULL TIME EQUIVALENT POSITIONS:		10.3	10.4	11.5	11.5	11.5

STRATEGY DESCRIPTION AND JUSTIFICATION:

This strategy captures the Institute's indirect costs to maintain the functions of a state agency.

EXTERNAL/INTERNAL FACTORS IMPACTING STRATEGY:

These operating costs provide for functions including executive administration, accounting and financial reporting, human services, internal audit, information technology infrastructure, and legal services.

542 Cancer Prevention and Research Institute of Texas

GOAL: 2 Indirect Administration
OBJECTIVE: 1 Indirect Administration
STRATEGY: 1 Indirect Administration

Service Categories:

Service: 09 Income: A.2 Age: B.3

CODE	DESCRIPTION	Exp 2019	Est 2020	Bud 2021	BL 2022	BL 2023
------	-------------	----------	----------	----------	---------	---------

EXPLANATION OF BIENNIAL CHANGE (includes Rider amounts):

<u>STRATEGY BIENNIAL TOTAL - ALL FUNDS</u>		<u>BIENNIAL CHANGE</u>	<u>EXPLANATION OF BIENNIAL CHANGE</u>	
<u>Base Spending (Est 2020 + Bud 2021)</u>	<u>Baseline Request (BL 2022 + BL 2023)</u>		<u>\$ Amount</u>	<u>Explanation(s) of Amount (must specify MOFs and FTEs)</u>
\$8,928,931	\$8,760,106	\$(168,825)	\$(85,000)	The amount of transfers authorized from the cancer research strategy (1.1.1) to cover other operating expenses in 2020-21.
			\$(61,825)	Unexpended balance for internal audit contract carried forward from FY 2019.
			\$(20,000)	In FY 2021 made budget adjustment moving \$20,000 from grant review and award operations (1.1.3) strategy to increase training budget
			\$(2,000)	Unspecified
			<u>\$(168,825)</u>	Total of Explanation of Biennial Change

SUMMARY TOTALS:

OBJECTS OF EXPENSE:	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968
METHODS OF FINANCE (INCLUDING RIDERS):				\$296,932,968	\$296,932,968
METHODS OF FINANCE (EXCLUDING RIDERS):	\$252,628,740	\$294,987,051	\$299,602,067	\$296,932,968	\$296,932,968
FULL TIME EQUIVALENT POSITIONS:	34.5	34.4	36.0	36.0	36.0

3.A.1. PROGRAM-LEVEL REQUEST SCHEDULE
87th Regular Session, Agency Submission, Version 1

Agency Code: 542		Agency: Cancer Prevention & Research Institute of Texas			Prepared By: Heidi McConnell					
Date: 9/25/2020		Program	Program Name	Legal Authority	2020-21 Base	Requested 2022	Requested 2023	Biennial Total 2022-23	Biennial Difference	
Strategy	Strategy Name	Priority							\$	%
1.1.1	Award Cancer Research Grants	5	Cancer Research	Health and Safety Code 102.203	\$371,893,791	\$176,134,073	\$176,134,073	\$352,268,146	(\$19,625,645)	-5.3%
1.1.1	Award Cancer Research Grants	6	Commercialization of Cancer Drugs, Diagnostics and Therapies		\$126,355,541	\$75,486,031	\$75,486,031	\$150,972,062	\$24,616,521	19.5%
1.1.2	Award Cancer Prevention Grants	4	Cancer Prevention	Health and Safety Code 102.203	\$56,120,157	\$28,046,081	\$28,046,081	\$56,092,162	(\$27,995)	0.0%
1.1.3	Grant Review and Award Operations	2	Grant Review and Award Operations	Health and Safety Code 102.251 and 102.260	\$29,837,066	\$12,159,914	\$12,159,914	\$24,319,828	(\$5,517,238)	-18.5%
1.1.3	Grant Review and Award Operations	3	Grant Compliance	Health and Safety Code 102.263	\$1,453,632	\$726,816	\$726,816	\$1,453,632	\$0	0.0%
2.1.1	Indirect Administration	1	Indirect Administration	Health and Safety Code 102.051	\$8,928,931	\$4,380,053	\$4,380,053	\$8,760,106	(\$168,825)	-1.9%
					\$594,589,118	\$296,932,968	\$296,932,968	\$593,865,936	(\$723,182)	-0.1%

Program Prioritization: Indicate the methodology or approach taken by the agency, court, or institution to determine the ranking of each program by priority.

The agency administrative operations programs are ranked higher than the three cancer grant programs because the infrastructure has to be in place to be able to administer the grant programs. Indirect Administration is first among the agency operations programs because it incorporates the agency IT infrastructure (Cloud, software, hardware, security, etc.), accounting, procurement and auditing as well as support for CPRIT's Oversight Committee. Without this program, none of the other programs could operate. Grant Review and Award Operations is second because it supports the infrastructure for the agency to make cancer grant awards and provides the resources for the Grant Compliance program ranked third. It is difficult to prioritize CPRIT's grant programs because they each provide unique benefits to Texans. Cancer Prevention is ranked fourth overall and first among the grant programs because it has the most widespread and immediate benefit to Texans, providing much-needed cancer screening services and education to the uninsured and underinsured in every county across the state. The Cancer Research program is ranked fifth overall and second among the grant programs because it has caused fundamental changes to cancer research in Texas through the recruitment of 213 stellar researchers to Texas academic institutions, increasing from 1 to 3 the NCI comprehensive designated cancer centers, adding 1 new designated cancer center, and providing greater access to cancer clinical trials through which Texans can get advanced levels of cancer care not available through health care providers. The Commercialization of Cancer Drugs, Diagnostics and Therapies program is ranked sixth overall or third among the grant programs because its impact has not yet been as broad or extensive as the other two cancer grant programs. However, this program has expanded the capabilities of private entities by funding 42 biotech companies that were started in, expanded in, or brought to Texas, stimulated greater follow-on investment in the CPRIT-funded companies from private sector venture funds and other investors, and created more than 10,100 permanent high quality jobs. CPRIT-funded companies have also provided greater access to Texans to advanced levels of care through cancer clinical trials. They also have discoveries, mostly cancer drugs, that are much further along the cancer research development spectrum to becoming drug therapies offered by health care providers to Texas cancer patients and others around the United States and world to cure or mitigate the effect of some cancers.

3.B. Rider Revisions and Additions Request

Agency Code: 542	Agency Name: Cancer Prevention and Research Institute of Texas	Prepared By: Heidi McConnell	Date: 7/21/2020	Request Level:
----------------------------	---	--	---------------------------	-----------------------

Current Rider Number	Page Number in 2020-21 GAA	Proposed Rider Language
----------------------------	----------------------------------	-------------------------

2

I-14

Texans Conquer Cancer and Cancer of Unknown Primary Origin Awareness Plates: Appropriation of License Plate Receipts. Included in the amounts appropriated above in Strategy A.1.2, Award Cancer Prevention Grants, is all license plate revenue collected on or after September 1, ~~2019~~2021 (estimated to be \$15,000~~11,000~~ in fiscal year ~~2020~~2022 and \$15,000~~11,000~~ in fiscal year ~~2021~~2023) from the sale of the Texans Conquer Cancer license plates as provided by Transportation Code, §504.620 and Cancer of Unknown Primary Origin Awareness license plates as provided by Transportation Code, §504.6201 and deposited to the credit of the License Plate Trust Fund No. 0802.

Any unexpended balances remaining as of August 31, ~~2020~~2022, in the appropriation made herein are appropriated to the Cancer Prevention and Research Institute of Texas for the fiscal year beginning September 1, ~~2020~~2022.

The rider has been updated to reflect the dates of the new biennium. The revenue estimate has also been decreased by \$4,000 due to ongoing declining actual revenue generated by specialty license plates.

4

I-15

Transfer Authority. The Cancer Prevention and Research Institute of Texas shall notify the Legislative Budget Board and Governor of all appropriations transfers allowed under Article IX, Section 14.01. ~~Notwithstanding Article IX, Section 14.01, Appropriation Transfers, no appropriations or unexpended balances may be transferred out of Strategy A.1.1, Award Cancer Research Grants, or Strategy A.1.2, Award Cancer Prevention Grants, unless the Cancer Prevention and Research Institute of Texas submits a written request to the Legislative Budget Board, in a format prescribed by the Legislative Budget Board, that provides information regarding the purposes for the transfer; and the Legislative Budget Board issues written approval. The written request must be submitted to the Legislative Budget Board no later than 45 days prior to the date the contract is expected to be needed by the agency.~~

The revision allows CPRIT's chief executive officer to transfer funds according to the same authority provided to executive administrators at all other state agencies to maximize operational efficiency while providing transparency about any budget transfer actions to the legislature and governor.

3.B. Rider Revisions and Additions Request (continued)

- 5 I-15 **Transfer to Department of State Health Services for the Cancer Registry.** Out of amounts appropriated above out of General Obligation Bond Proceeds to the Cancer Prevention and Research Institute of Texas is \$3,118,02 out of General Obligation Bond Proceeds each fiscal year of the ~~2020-21~~2022-23 biennium which shall be transferred to the Department of State Health Services in Strategy A.1.2, Health Registries, Information, and Vital Records, for administration of the Cancer Registry in accordance with the Texas Constitution, Article III, Section 67 and Health and Safety Code, Chapter 102.

The rider has been updated to reflect the dates of the new biennium.

- 8 I-15 **Unexpended Balances Within the Biennium.** Any unexpended balances remaining as of August 31, ~~2020~~2022, in the appropriations made above are appropriated for the fiscal year beginning September 1, ~~2020~~2022.

The Cancer Prevention and Research Institute of Texas shall report the amount of unexpended balances remaining as of August 31, ~~2020~~2022 and carried forward into the fiscal year beginning September 1, ~~2020~~2022 to the Legislative Budget Board no later than 30 days after the end of the fiscal year.

The rider has been updated to reflect the dates of the new biennium.

- 9 I-15 **Unexpended Balances Between Biennia.** Included in amounts appropriated above are any unexpended balances out of General Obligation Bond Proceeds (estimated to be \$0) remaining as of August 31, ~~2019~~2021 in appropriations made to the Cancer Prevention and Research Institute of Texas for the same purpose for the biennium beginning September 1, ~~2019~~2021.

The Cancer Prevention and Research Institute of Texas shall report the amount of unexpended balances remaining as of August 31, ~~2019~~2021, and carried forward into the fiscal year beginning September 1, ~~2019~~2021, to the Legislative Budget Board no later than 30 days after the end of the fiscal year.

The rider has been updated to reflect the dates of the new biennium.

4.A. Exceptional Item Request Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 4:05:20PM

Agency code: 542

Agency name:

Cancer Prevention and Research Institute of Texas

CODE	DESCRIPTION		Excp 2022	Excp 2023
<p style="text-align: right;"> Item Name: Maintain Level Funding for Grant Review and Award Operation Item Priority: 1 IT Component: No Anticipated Out-year Costs: No Involve Contracts > \$50,000: Yes </p>				
<p> Includes Funding for the Following Strategy or Strategies: 01-01-01 Award Cancer Research Grants 01-01-02 Award Cancer Prevention Grants 01-01-03 Grant Review and Award Operations </p>				
OBJECTS OF EXPENSE:				
2001	PROFESSIONAL FEES AND SERVICES		2,699,376	2,699,376
4000	GRANTS		-2,699,376	-2,699,376
TOTAL, OBJECT OF EXPENSE			\$0	\$0
METHOD OF FINANCING:				
780	Bond Proceed-Gen Obligat		0	0
TOTAL, METHOD OF FINANCING			\$0	\$0

DESCRIPTION / JUSTIFICATION:

CPRIT requires an adjustment to address an annual appropriation shortfall for on-going grant review and award operating costs including Review Council honoraria, grant revenue asset management with the Texas Safekeeping Trust Company, product development grant application due diligence, and outsourced pre- and post-award grant management support costs.

EXTERNAL/INTERNAL FACTORS:

Due to a rise in workload and membership for the review council chairs, Review Council honoraria was modified in the agency's Honoraria Policy adopted for FY 2020. More product development grant applications undergoing due diligence evaluations has resulted in increased costs for the outsourced due diligence evaluation services. The need to implement and maintain information security enhancements to the electronic grant management platform has resulted in increased costs to the outsourced pre- and post-award grant management support contract. There are also additional costs for the contract CPRIT initiated with the Texas Safekeeping Trust Company in FY 2021 to provide asset management expertise to the agency to ensure the state's interest in CPRIT company grant assets are actively managed for maximum benefit to the state.

PCLS TRACKING KEY:

4.A. Exceptional Item Request Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: **9/28/2020**
TIME: **4:05:20PM**

Agency code: **542**

Agency name:

Cancer Prevention and Research Institute of Texas

CODE	DESCRIPTION	Excp 2022	Excp 2023
-------------	--------------------	------------------	------------------

APPROXIMATE PERCENTAGE OF EXCEPTIONAL ITEM : 91.00%

CONTRACT DESCRIPTION :

Pre- and Post-Award Grant Management Support services - Ongoing

Product Development Research Grant Application Due Diligence Evaluation- Ongoing

Interagency Contract with The Texas Safekeeping Trust Company for management of CPRIT's company grant assets - Ongoing

4.A. Exceptional Item Request Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 4:05:20PM

Agency code: 542

Agency name:

Cancer Prevention and Research Institute of Texas

CODE	DESCRIPTION	Excp 2022	Excp 2023
------	-------------	-----------	-----------

Item Name:	8 New Grant Program, Compliance and Accounting Support
Item Priority:	2
IT Component:	No
Anticipated Out-year Costs:	No
Involve Contracts > \$50,000:	No
Includes Funding for the Following Strategy or Strategies:	01-01-01 Award Cancer Research Grants 01-01-02 Award Cancer Prevention Grants 01-01-03 Grant Review and Award Operations 02-01-01 Indirect Administration

OBJECTS OF EXPENSE:

1001	SALARIES AND WAGES	572,789	572,789
2009	OTHER OPERATING EXPENSE	38,328	20,840
4000	GRANTS	-611,117	-593,629
TOTAL, OBJECT OF EXPENSE		\$0	\$0

METHOD OF FINANCING:

780	Bond Proceed-Gen Obligat	0	0
TOTAL, METHOD OF FINANCING		\$0	\$0

FULL-TIME EQUIVALENT POSITIONS (FTE):

8.00	8.00
------	------

DESCRIPTION / JUSTIFICATION:

CPRIT requests eight (8) new full-time equivalent (FTE) positions for additional compliance/accounting and program workload demand. The request includes: 2 new Grant Accountants who will specialize in reviewing the financial reports of product development research grantees, 1 new Accountant who will primarily support grant payment processing but also provide support on general agency budget and accounting to back up the Agency Accountant, 3 new Grant Compliance Specialists to address the increasing workload of performing the necessary annual grant compliance reviews, monitoring visits, and trainings for CPRIT's portfolio of 550+ active grants, 1 new Program Manager for the Academic Research Program to address the increasing programmatic workload in RFA development, tracking grant reporting documentation, data collection and analysis, and summarization of grant results, and 1 new Program Manager for the Product Development Research Program to address the increasing workload in reviewing and evaluating grant progress, monitoring the grant portfolio project metrics, data collection and analysis, summarization of grant results, and program outreach efforts across the state.

EXTERNAL/INTERNAL FACTORS:

While CPRIT is sensitive to the need to keep overhead as low as possible, the extremely low ratio of less than 2% between annual operating costs and total funds of \$1.4 billion under active management may indicate insufficient resources dedicated to compliance, fiscal and program monitoring activities. There are no comparable grant making entities with a defined statutory compliance program like CPRIT's. The National Institutes of Health operate on trust and work with their grantees on policy questions but

4.A. Exceptional Item Request Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 4:05:20PM

Agency code: 542

Agency name:

Cancer Prevention and Research Institute of Texas

CODE	DESCRIPTION	Excp 2022	Excp 2023
------	-------------	-----------	-----------

don't verify research progress or expenditure accountability prior to disbursing grant funds . CPRIT's analysis of compliance program monitoring hours dedicated to 10 distinct, required processes indicates an appropriate staffing level of 9.15 FTEs. CPRIT currently has 6 compliance staff so requests 3 additional compliance personnel to fill this gap. CPRIT currently has 5 grant accountants and distributes product development research (PDR) grants among them, so they each have 2-4 of these grants plus 80-100+ academic research and prevention grants. Because the review of PDR grant financial reports can be more time consuming due to additional complexity than that of other grants, having 2 grant accounting FTEs dedicated to PDR grants will allow for greater efficiency and effectiveness to process those reports and also allow the other 5 grant accounting FTEs to be more efficient and effective in processing the reports for academic research and prevention grants. The 2 program manager FTEs, which have not increased since 2013, will address increased workload demand resulting from a rise in research grant results data from both the awards under active management as well as completed grant awards and the demand for program resource availability.

PCLS TRACKING KEY:

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:		Maintain Level Funding for Grant Review and Award Operation			
Allocation to Strategy:		1-1-1	Award Cancer Research Grants		
OBJECTS OF EXPENSE:					
	4000	GRANTS		-2,429,438	-2,429,438
TOTAL, OBJECT OF EXPENSE					
METHOD OF FINANCING:					
	780	Bond Proceed-Gen Obligat		-2,429,438	-2,429,438
TOTAL, METHOD OF FINANCING					

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:		Maintain Level Funding for Grant Review and Award Operation			
Allocation to Strategy:		1-1-2	Award Cancer Prevention Grants		
OBJECTS OF EXPENSE:					
	4000 GRANTS			-269,938	-269,938
TOTAL, OBJECT OF EXPENSE				-\$269,938	-\$269,938
METHOD OF FINANCING:					
	780 Bond Proceed-Gen Obligat			-269,938	-269,938
TOTAL, METHOD OF FINANCING				-\$269,938	-\$269,938

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:		Maintain Level Funding for Grant Review and Award Operation			
Allocation to Strategy:		1-1-3	Grant Review and Award Operations		
OBJECTS OF EXPENSE:					
	2001	PROFESSIONAL FEES AND SERVICES		2,699,376	2,699,376
TOTAL, OBJECT OF EXPENSE				\$2,699,376	\$2,699,376
METHOD OF FINANCING:					
	780	Bond Proceed-Gen Obligat		2,699,376	2,699,376
TOTAL, METHOD OF FINANCING				\$2,699,376	\$2,699,376

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:	8 New Grant Program, Compliance and Accounting Support				
Allocation to Strategy:	1-1-1	Award Cancer Research Grants			
OBJECTS OF EXPENSE:					
	4000 GRANTS			-550,005	-534,266
TOTAL, OBJECT OF EXPENSE				-\$550,005	-\$534,266
METHOD OF FINANCING:					
	780 Bond Proceed-Gen Obligat			-550,005	-534,266
TOTAL, METHOD OF FINANCING				-\$550,005	-\$534,266

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:	8 New Grant Program, Compliance and Accounting Support				
Allocation to Strategy:	1-1-2	Award Cancer Prevention Grants			
OBJECTS OF EXPENSE:					
	4000	GRANTS		-61,112	-59,363
TOTAL, OBJECT OF EXPENSE				- \$61,112	- \$59,363
METHOD OF FINANCING:					
	780	Bond Proceed-Gen Obligat		-61,112	-59,363
TOTAL, METHOD OF FINANCING				- \$61,112	- \$59,363

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:	8 New Grant Program, Compliance and Accounting Support				
Allocation to Strategy:	1-1-3	Grant Review and Award Operations			
OUTPUT MEASURES:					
1	Number of Grants Reviewed for Compliance			20.00	40.00
OBJECTS OF EXPENSE:					
1001	SALARIES AND WAGES			512,789	512,789
TOTAL, OBJECT OF EXPENSE				\$512,789	\$512,789
METHOD OF FINANCING:					
780	Bond Proceed-Gen Obligat			512,789	512,789
TOTAL, METHOD OF FINANCING				\$512,789	\$512,789
FULL-TIME EQUIVALENT POSITIONS (FTE):				7.0	7.0

Agency code:	542	Agency name:	Cancer Prevention and Research Institute of Texas		
Code	Description			Excp 2022	Excp 2023
Item Name:	8 New Grant Program, Compliance and Accounting Support				
Allocation to Strategy:	2-1-1	Indirect Administration			
OBJECTS OF EXPENSE:					
1001	SALARIES AND WAGES			60,000	60,000
2009	OTHER OPERATING EXPENSE			38,328	20,840
TOTAL, OBJECT OF EXPENSE				\$98,328	\$80,840
METHOD OF FINANCING:					
780	Bond Proceed-Gen Obligat			98,328	80,840
TOTAL, METHOD OF FINANCING				\$98,328	\$80,840
FULL-TIME EQUIVALENT POSITIONS (FTE):				1.0	1.0

4.C. Exceptional Items Strategy Request
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 6:02:27PM

Agency Code: **542** Agency name: **Cancer Prevention and Research Institute of Texas**

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 1 Award Cancer Research Grants

Service: 21 Income: A.2 Age: B.3

CODE DESCRIPTION	Excp 2022	Excp 2023
------------------	-----------	-----------

OBJECTS OF EXPENSE:

4000 GRANTS	(2,979,443)	(2,963,704)
Total, Objects of Expense	\$(2,979,443)	\$(2,963,704)

METHOD OF FINANCING:

780 Bond Proceed-Gen Obligat	(2,979,443)	(2,963,704)
Total, Method of Finance	\$(2,979,443)	\$(2,963,704)

EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:

Maintain Level Funding for Grant Review and Award Operation

8 New Grant Program, Compliance and Accounting Support

4.C. Exceptional Items Strategy Request
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 6:02:27PM

Agency Code: **542** Agency name: **Cancer Prevention and Research Institute of Texas**

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 2 Award Cancer Prevention Grants

Service: 23 Income: A.2 Age: B.3

CODE	DESCRIPTION	Excp 2022	Excp 2023
------	-------------	-----------	-----------

OBJECTS OF EXPENSE:

4000	GRANTS	(331,050)	(329,301)
Total, Objects of Expense		\$(331,050)	\$(329,301)

METHOD OF FINANCING:

780	Bond Proceed-Gen Obligat	(331,050)	(329,301)
Total, Method of Finance		\$(331,050)	\$(329,301)

EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:

Maintain Level Funding for Grant Review and Award Operation

8 New Grant Program, Compliance and Accounting Support

4.C. Exceptional Items Strategy Request
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 6:02:27PM

Agency Code: **542** Agency name: **Cancer Prevention and Research Institute of Texas**

GOAL: 1 Create and Expedite Innovation in Cancer Research and Prevention Servs

OBJECTIVE: 1 Cancer Research and Prevention Projects

Service Categories:

STRATEGY: 3 Grant Review and Award Operations

Service: 09 Income: A.2 Age: B.3

CODE	DESCRIPTION	Excp 2022	Excp 2023
------	-------------	-----------	-----------

OUTPUT MEASURES:

1 Number of Grants Reviewed for Compliance	20.00	40.00
---	-------	-------

OBJECTS OF EXPENSE:

1001 SALARIES AND WAGES	512,789	512,789
2001 PROFESSIONAL FEES AND SERVICES	2,699,376	2,699,376
Total, Objects of Expense	\$3,212,165	\$3,212,165

METHOD OF FINANCING:

780 Bond Proceed-Gen Obligat	3,212,165	3,212,165
Total, Method of Finance	\$3,212,165	\$3,212,165

FULL-TIME EQUIVALENT POSITIONS (FTE):

7.0	7.0
-----	-----

EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:

Maintain Level Funding for Grant Review and Award Operation

8 New Grant Program, Compliance and Accounting Support

4.C. Exceptional Items Strategy Request
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

DATE: 9/28/2020
TIME: 6:02:27PM

Agency Code: **542** Agency name: **Cancer Prevention and Research Institute of Texas**

GOAL: 2 Indirect Administration

OBJECTIVE: 1 Indirect Administration

STRATEGY: 1 Indirect Administration

Service Categories:

Service: 09 Income: A.2 Age: B.3

CODE	DESCRIPTION	Excp 2022	Excp 2023
------	-------------	-----------	-----------

OBJECTS OF EXPENSE:

1001	SALARIES AND WAGES	60,000	60,000
------	--------------------	--------	--------

2009	OTHER OPERATING EXPENSE	38,328	20,840
------	-------------------------	--------	--------

Total, Objects of Expense		\$98,328	\$80,840
----------------------------------	--	-----------------	-----------------

METHOD OF FINANCING:

780	Bond Proceed-Gen Obligat	98,328	80,840
-----	--------------------------	--------	--------

Total, Method of Finance		\$98,328	\$80,840
---------------------------------	--	-----------------	-----------------

FULL-TIME EQUIVALENT POSITIONS (FTE):	1.0	1.0
--	-----	-----

EXCEPTIONAL ITEM(S) INCLUDED IN STRATEGY:

8 New Grant Program, Compliance and Accounting Support

6.A. Historically Underutilized Business Supporting Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:29:50PM

Agency Code: 542 Agency: Cancer Prevention and Research Institute of Texas

COMPARISON TO STATEWIDE HUB PROCUREMENT GOALS

A. Fiscal Year - HUB Expenditure Information

Statewide HUB Goals	Procurement Category	% Goal	HUB Expenditures FY 2018			Total Expenditures		HUB Expenditures FY 2019			Total Expenditures	
			% Actual	Diff	Actual \$	FY 2018	% Goal	% Actual	Diff	Actual \$	FY 2019	
11.2%	Heavy Construction	0.0 %	0.0%	0.0%	\$0	\$0	0.0 %	0.0%	0.0%	\$0	\$0	
21.1%	Building Construction	0.0 %	0.0%	0.0%	\$0	\$0	0.0 %	0.0%	0.0%	\$0	\$0	
32.9%	Special Trade	0.0 %	0.0%	0.0%	\$0	\$0	0.0 %	0.0%	0.0%	\$0	\$0	
23.7%	Professional Services	23.7 %	16.2%	-7.5%	\$40,000	\$247,308	23.7 %	22.7%	-1.0%	\$40,000	\$175,856	
26.0%	Other Services	26.0 %	4.9%	-21.1%	\$351,909	\$7,233,788	26.0 %	4.3%	-21.7%	\$551,542	\$12,834,732	
21.1%	Commodities	21.1 %	54.3%	33.2%	\$137,382	\$252,816	21.1 %	41.0%	19.9%	\$138,931	\$338,988	
	Total Expenditures		6.8%		\$529,291	\$7,733,912		5.5%		\$730,473	\$13,349,576	

B. Assessment of Fiscal Year - Efforts to Meet HUB Procurement Goals

Attainment:

The agency attained or exceeded 1 of 3, or 33% of the applicable agency HUB procurement goals in fiscal year 2018.

The agency attained or exceeded 1 of 3, or 33% of the applicable agency HUB procurement goals in fiscal year 2019.

Applicability:

CPRIT does not perform heavy construction, building construction, or special trade construction so these HUB categories are not applicable to the agency.

Factors Affecting Attainment:

CPRIT must procure accounting and audit professional services for the statutorily required internal audit program and annual independent financial audit . CPRIT has procured independent financial audit services from a certified HUB vendor but has not been able to procure a firm for internal audit due to the limited number of certified HUB vendors in this category.

Other Services comprise the bulk of CPRIT purchases which includes specialized services such as grant management support, outside counsel, business and regulatory due diligence, and a cost of cancer economic assessment. There are very few vendors that provide some of these specialized services like grant management support and business and regulatory due diligence in the U.S., and none in Texas. As a result, there's a corresponding lack of certified HUB vendors for these services. Honoraria payments to CPRIT's peer review chairs who lead the grant application evaluations are in this category. They are recruited for their scientific expertise and must live outside the state, so they can't be certified HUB vendors.

"Good-Faith" Efforts:

6.A. Historically Underutilized Business Supporting Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: **9/22/2020**
Time: **6:29:50PM**

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

CPRIT is continuously implementing strategies to increase the agency's HUB participation and ensure the agency complies with the laws and rules established for the HUB program. This compliance includes adherence to HUB planning and reporting requirements and to HUB purchasing procedures established by SPD. As part of the effort to increase HUB participation, the purchaser must ensure that procurement opportunities are distributed among HUB groups, not concentrated within one or two HUB groups.

CPRIT uses the following services and outreach activities to increase the utilization of HUB vendors in its procurement processes:

- Utilizing the SPD Centralized Master Bidders List and HUB search to ensure that all eligible certified HUBs are notified of CPRIT's procurement opportunities;
- Utilizing HUB resellers from the Department of Information Resources' information technology contracts as often as possible;
- Attending HUB Workgroup Discussion meetings;
- Attending HUB small business trainings and HUB forums to increase awareness of CPRIT procurement opportunities among HUB vendors; and
- Participating in available meetings with HUB vendors at other agencies.

6.E. Estimated Revenue Collections Supporting Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Agency Code: **542** Agency name: **Cancer Prevention and Research Institute of Texas**

FUND/ACCOUNT	Act 2019	Exp 2020	Est 2021	Est 2022	Est 2023
<u>666</u> Appropriated Receipts					
Beginning Balance (Unencumbered):	\$24,450	\$50,497	\$0	\$0	\$0
Estimated Revenue:					
3802 Reimbursements-Third Party	47,600	40,000	40,000	40,000	40,000
Subtotal: Actual/Estimated Revenue	47,600	40,000	40,000	40,000	40,000
Total Available	\$72,050	\$90,497	\$40,000	\$40,000	\$40,000
DEDUCTIONS:					
Product Development Research Review Expenses	(21,553)	(90,497)	(40,000)	(40,000)	(40,000)
Unexpended Balance-PDR Grant Application Fee Revenue	(50,497)	0	0	0	0
Total, Deductions	\$(72,050)	\$(90,497)	\$(40,000)	\$(40,000)	\$(40,000)
Ending Fund/Account Balance	\$0	\$0	\$0	\$0	\$0

REVENUE ASSUMPTIONS:

For the product development research program, CPRIT requires that applicants pay a fee of either \$500 or \$1,000 based on the type of grant mechanism application to ensure that the applications are not frivolous and to defray some of the additional cost associated with evaluation of these applications. The product development research grant application evaluation is composed of not only peer review but also business, regulatory and intellectual property due diligence which results in an additional expense not necessary for academic research or prevention grant application evaluations. The fees generate approximately \$40,000 per year in third-party reimbursements. CPRIT had to cancel its cancer research and prevention innovations conference scheduled to be held July 2020 due to the COVID-19 pandemic disaster. As a result, there are no conference registration fee revenue or conference expenses to report.

CONTACT PERSON:

Dan Limas

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

SCIENTIFIC AND PREVENTION ADVISORY COMMITTEE

Statutory Authorization: Health and Safety Code, Sec. 102.155
Number of Members: 200
Committee Status: Ongoing
Date Created: 06/19/2009
Date to Be Abolished: 08/31/2023
Strategy (Strategies): 1-1-3 GRANT REVIEW AND AWARD OPERATIONS

	Expended Exp 2019	Estimated Est 2020	Budgeted Bud 2021	Requested BL 2022	Requested BL 2023
Advisory Committee Costs					
Committee Members Direct Expenses					
TRAVEL	\$214,644	\$116,231	\$0	\$0	\$0
OTHER OPERATING COSTS	1,701,069	1,541,263	1,286,000	1,286,000	1,286,000
HONORARIA	2,100,700	2,185,600	2,027,100	2,273,600	2,273,600
Other Expenditures in Support of Committee Activities					
TRAVEL	11,834	5,312	0	0	0
PERSONNEL	240,677	234,322	234,322	234,322	234,322
Total, Committee Expenditures	\$4,268,924	\$4,082,728	\$3,547,422	\$3,793,922	\$3,793,922
Method of Financing					
Bond Proceeds - GO Bonds	\$4,268,924	\$4,082,728	\$3,547,422	\$3,793,922	\$3,793,922
Total, Method of Financing	\$4,268,924	\$4,082,728	\$3,547,422	\$3,793,922	\$3,793,922
Meetings Per Fiscal Year	21	20	29	36	36

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

Description and Justification for Continuation/Consequences of Abolishing

The Scientific Research and Prevention Program Committee (SRPPC) conducts CPRIT's expert peer review of all cancer prevention, academic research and product development research grant applications. Members of the committee provide an independent evaluation of each grant application received by CPRIT. Their evaluations are the basis of grant award recommendations considered and approved by the Oversight Committee. The peer review committees are the cornerstone of CPRIT's processes to fund the best evidence-based cancer prevention services and academic and product development cancer research projects. Without the independent evaluations of the peer review committees, CPRIT would have difficulty making grant funding decisions and achieving its mission to expedite discoveries and innovations that reduce the burdens of cancer.

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

UNIVERSITY ADVISORY COMMITTEE

Statutory Authorization: Health and Safety Code, Sec. 102.154
Number of Members: 12
Committee Status: Ongoing
Date Created: 6/19/2009
Date to Be Abolished: 08/31/2023
Strategy (Strategies): 1-1-3 GRANT REVIEW AND AWARD OPERATIONS

Advisory Committee Costs	Expended Exp 2019	Estimated Est 2020	Budgeted Bud 2021	Requested BL 2022	Requested BL 2023
Other Expenditures in Support of Committee Activities					
TRAVEL	\$366	\$437	\$0	\$500	\$500
PERSONNEL	11,856	18,245	12,163	12,163	12,163
Total, Committee Expenditures	\$12,222	\$18,682	\$12,163	\$12,663	\$12,663
Method of Financing					
Bond Proceeds - GO Bonds	\$12,222	\$18,682	\$12,163	\$12,663	\$12,663
Total, Method of Financing	\$12,222	\$18,682	\$12,163	\$12,663	\$12,663
Meetings Per Fiscal Year	2	3	2	2	2

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

Description and Justification for Continuation/Consequences of Abolishing

The primary purpose of the University Advisory Committee (UAC) is to advise the Oversight Committee and the Scientific Research and Prevention Program Committees regarding the role of institutions of higher education in cancer research, including early stage product development. If the UAC were abolished, the Oversight Committee would lose valuable insight from Texas institutions of higher education about academic cancer research priorities and the value of different types of grant funding mechanisms.

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

ADVISORY COMMITTEE ON CHILDHOOD CANCER

Statutory Authorization: Health and Safety Code, Sec. 102.155
Number of Members: 20
Committee Status: Ongoing
Date Created: 6/19/2009
Date to Be Abolished: 08/31/2023
Strategy (Strategies): 1-1-3 GRANT REVIEW AND AWARD OPERATIONS

Advisory Committee Costs	Expended Exp 2019	Estimated Est 2020	Budgeted Bud 2021	Requested BL 2022	Requested BL 2023
Other Expenditures in Support of Committee Activities					
TRAVEL	\$0	\$1,264	\$0	\$0	\$0
PERSONNEL	11,856	12,163	12,163	12,163	12,163
Total, Committee Expenditures	\$11,856	\$13,427	\$12,163	\$12,163	\$12,163
Method of Financing					
Bond Proceeds - GO Bonds	\$11,856	\$13,427	\$12,163	\$12,163	\$12,163
Total, Method of Financing	\$11,856	\$13,427	\$12,163	\$12,163	\$12,163
Meetings Per Fiscal Year	2	2	2	2	2

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

Description and Justification for Continuation/Consequences of Abolishing

The Advisory Committee on Childhood Cancer (ACCC) advises the Oversight Committee on the impact of CPRIT funding of innovative research grant projects that prevent, control or treat pediatric cancers and on new grant award mechanisms that encourage additional research in these areas. The ACCC is composed of pediatric oncologists and parents of pediatric cancer patients appointed by the Oversight Committee. If the ACCC were abolished, the Oversight Committee would lose this valuable insight and advice.

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

PRODUCT DEVELOPMENT ADVISORY COMMITTEE

Statutory Authorization: Health and Safety Code, Sec. 102.155
Number of Members: 17
Committee Status: Ongoing
Date Created: 9/1/2014
Date to Be Abolished: 08/31/2023
Strategy (Strategies): 1-1-3 GRANT REVIEW AND AWARD OPERATIONS

Advisory Committee Costs	Expended Exp 2019	Estimated Est 2020	Budgeted Bud 2021	Requested BL 2022	Requested BL 2023
Other Expenditures in Support of Committee Activities					
PERSONNEL	\$3,329	\$6,975	\$13,949	\$13,949	\$13,949
Total, Committee Expenditures	\$3,329	\$6,975	\$13,949	\$13,949	\$13,949
Method of Financing					
Bond Proceeds - GO Bonds	\$3,329	\$6,975	\$13,949	\$13,949	\$13,949
Total, Method of Financing	\$3,329	\$6,975	\$13,949	\$13,949	\$13,949
Meetings Per Fiscal Year	0	1	2	2	2

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

Description and Justification for Continuation/Consequences of Abolishing

The Product Development Advisory Committee (PDAC) advises the Oversight Committee on key issues related to the product development research program including fair revenue sharing terms and the appropriate mix of product development awards by stage of company and size of award in CPRIT's grant portfolio. The PDAC is composed of individuals with any combination of scientific, business and legal backgrounds who have experience with life sciences start-up companies. The members are appointed by the Oversight Committee. If the PDAC were abolished, the Oversight Committee would lose valuable insight about Texas' environment for life sciences start-up companies, like the ones receiving CPRIT awards, as well as advice on the key issues described above.

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

PREVENTION ADVISORY COMMITTEE

Statutory Authorization: Health and Safety Code, Sec. 102.155
Number of Members: 7
Committee Status: New
Date Created: 3/9/2020
Date to Be Abolished: 08/31/2023
Strategy (Strategies): 1-1-3 GRANT REVIEW AND AWARD OPERATIONS

Advisory Committee Costs	Expended Exp 2019	Estimated Est 2020	Budgeted Bud 2021	Requested BL 2022	Requested BL 2023
Other Expenditures in Support of Committee Activities					
PERSONNEL	\$0	\$4,923	\$4,923	\$4,923	\$4,923
Total, Committee Expenditures	\$0	\$4,923	\$4,923	\$4,923	\$4,923
Method of Financing					
Bond Proceeds - GO Bonds	\$0	\$4,923	\$4,923	\$4,923	\$4,923
Total, Method of Financing	\$0	\$4,923	\$4,923	\$4,923	\$4,923
Meetings Per Fiscal Year	0	1	2	2	2

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

Description and Justification for Continuation/Consequences of Abolishing

The Prevention Advisory Committee (PAC) advises the Oversight Committee on key issues surrounding cancer prevention and control. The members of the PAC share their advice on opportunities to increase CPRIT's impact on cancer prevention and control in Texas. If the PAC were abolished, the Oversight Committee would lose valuable insight from experts in the field of cancer prevention and control on the most efficient and effective ways to increase cancer prevention as well as decrease the incidence and mortality cancer rates in Texas.

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

CLINICAL TRIAL ADVISORY COMMITTEE

Statutory Authorization: Health and Safety Code, Sec. 102.155
Number of Members: 9
Committee Status: Ongoing
Date Created: 5/16/2018
Date to Be Abolished: 08/31/2023
Strategy (Strategies): 1-1-3 GRANT REVIEW AND AWARD OPERATIONS

Advisory Committee Costs	Expended Exp 2019	Estimated Est 2020	Budgeted Bud 2021	Requested BL 2022	Requested BL 2023
Other Expenditures in Support of Committee Activities					
PERSONNEL	\$11,856	\$6,082	\$12,163	\$12,163	\$12,163
Total, Committee Expenditures	\$11,856	\$6,082	\$12,163	\$12,163	\$12,163
Method of Financing					
Bond Proceeds - GO Bonds	\$11,856	\$6,082	\$12,163	\$12,163	\$12,163
Total, Method of Financing	\$11,856	\$6,082	\$12,163	\$12,163	\$12,163
Meetings Per Fiscal Year	2	1	2	2	2

6.F.a. Advisory Committee Supporting Schedule ~ Part A

87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Date: 9/22/2020
Time: 6:31:32PM

Agency Code: **542** Agency: **Cancer Prevention and Research Institute of Texas**

Description and Justification for Continuation/Consequences of Abolishing

The Clinical Trial Advisory Committee (CTAC) advises the Oversight Committee on the impact of current CPRIT mechanisms supporting clinical trials; opportunities to increase CPRIT's impact on translating basic discoveries to clinical trials; and on mechanisms that would address barriers to patient enrollment in therapeutic clinical trials. Without the CTAC, the Oversight Committee would lose valuable expertise and insights that improve and increase the number of clinical trials funded through CPRIT grant awards. The agency's activities related to clinical trials is a high priority focus for the agency.

6.E. Estimated Revenue Collections Supporting Schedule
87th Regular Session, Agency Submission, Version 1
Automated Budget and Evaluation System of Texas (ABEST)

Agency Code: **542** Agency name: **Cancer Prevention and Research Institute of Texas**

FUND/ACCOUNT	Act 2019	Exp 2020	Est 2021	Est 2022	Est 2023
<u>802</u> Lic Plate Trust Fund No. 0802, est					
Beginning Balance (Unencumbered):	\$10,882	\$21,178	\$0	\$0	\$0
Estimated Revenue:					
3001 Fed Receipts Matched-Transport Pgm	10,296	15,000	15,000	11,000	11,000
Subtotal: Actual/Estimated Revenue	10,296	15,000	15,000	11,000	11,000
Total Available	\$21,178	\$36,178	\$15,000	\$11,000	\$11,000
DEDUCTIONS:					
Prevention Grant Patient Support Service	0	(36,178)	(15,000)	(11,000)	(11,000)
Unexpended Balance-Prevention Grant Patient Support Services	(21,178)	0	0	0	0
Total, Deductions	\$(21,178)	\$(36,178)	\$(15,000)	\$(11,000)	\$(11,000)
Ending Fund/Account Balance	\$0	\$0	\$0	\$0	\$0

REVENUE ASSUMPTIONS:

License plate fees are collected through the Texas Department of Motor Vehicles. The license plate revenue is used to pay for patient support services that may be funded through CPRIT's cancer prevention grants. The revenue from the cancer license plates has been steadily declining as other specialty license plates, including some for cancer, have become available. Therefore, the estimates for the 2022-23 biennium have been decreased to \$11,000 per year.

CONTACT PERSON:

Dan Limas

6.L. Document Production Standards

Summary of Savings Due to Improved Document Production Standards

Agency Code:	Agency Name:	Prepared By:
542	Cancer Prevention & Research Institute of Texas	

Documented Production Standards Strategies	Estimated 2020	Budgeted 2021
1. Copier / Printer Default Adjustments and Online Document Sharing	\$9,327	\$6,610
2.	\$0	\$0
3.	\$0	\$0
4.	\$0	\$0
Total, All Strategies	\$9,327	\$6,610
Total Estimated Paper Volume Reduced	33%	25%

Description:
CPRIT maintained document production standards with the adjustment of default setting on the two agency large volume copier/printers (e.g., Xerox and Canon) to print documents double-sided and in black and white. CPRIT continues to encourage transmitting documents electronically in lieu of printing hard copies. The dramatic improvement in document production standards is the result of the agency staff having to work remotely beginning March 22, 2020, due to the COVID-19 pandemic disaster which required online review of grant financial reports and saving vouchers and other accounting documents in electronic format exclusively instead of printing them. This was possible because CPRIT had already Adobe Acrobat Pro software licenses in FY 2018 to all grant accountant and grant compliance staff computers to facilitate the online review of grant financial report supporting documentation instead of printing these large volume documents.